Big Pharma’s Strategy: Leveraging the WHO

A new investigative report by Max Jones reveals Big Pharma’s strategy to address a looming “patent cliff” by taking over the public sector, particularly the WHO, to bypass regulatory hurdles and secure market dominance. The pharmaceutical industry is facing the expiration of many blockbuster drug patents by 2030 making them shift focus to complex biologics that are harder to replicate and regulate. The WHO, influenced by private stakeholders like Bill Gates, is implementing amendments and a pandemic treaty to facilitate this. This strategy aims to institutionalize fast-tracked, deregulated drug development seen during the COVID-19 pandemic. Critics warn this could lead to forced consumption and a loss of civil liberties globally.

Editor’s Note: The WHO’s involvement and significant funding from private stakeholders like Bill Gates suggest a troubling alliance where public health policies could be swayed by corporate interests. The rapid development and global distribution of COVID-19 vaccines showcased the risks of fast-tracked, deregulated drug approval processes. Is this what we still want? As the WHO pushes for amendments and treaties that could institutionalize these practices, it raises serious concerns about the erosion of regulatory safeguards, potentially compromising safety in favor of profitability. [See also: The Intertwined Interests of Global Health Initiatives and Pharmaceutical Dominance, How Public’s Confidence in Big Pharma Fuels Greed and Deception]

Read Original Article